MyFinsight
Home
Blog
About
Contact
Download
Download image
Net income
$204,831K
Proceeds from exercise of
stock options
$22,661K
Stock-based compensation
expense, net
$54,514K
Accrued rebates
$21,268K
Accrued expenses and
other current...
$14,104K
Depreciation
$5,724K
Other long-term
liabilities
$2,280K
Amortization of operating
lease right-of-use...
$827K
Accounts payable
$826K
Other, net
$684K
Net cash provided by
(used in) operating...
$200,865K
Net cash provided by
financing activities
$8,705K
Effect of exchange rate
changes on cash and cash...
$286K
Canceled cashflow
$104,193K
Canceled cashflow
$13,956K
Net change in cash
and cash...
$151,439K
Canceled cashflow
$58,417K
Accrued legal
settlement
-$31,250K
Deferred tax asset
$22,845K
Accounts receivable, net
$22,124K
Prepaid taxes
$12,389K
Inventory
$6,286K
Realized gain on
investments
$5,953K
Prepaid expenses and
other assets
$2,270K
Lease liability
-$578K
Accretion of marketable
securities
-$498K
Maturities of investments
$375,639K
Proceeds from disposal of
assets
$435K
Taxes paid for
employee tax withholding...
$12,144K
Taxes paid for
employee tax withholding...
$1,812K
Net cash (used in)
provided by investing...
-$58,417K
Canceled cashflow
$376,074K
Purchases of investments
$422,540K
Purchases of property and
equipment
$11,951K
Back
Back
Cash Flow
source: myfinsight.com
Krystal Biotech, Inc. (KRYS)
Krystal Biotech, Inc. (KRYS)